Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., . . . Weller, M. (2020). Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The checkmate 143 phase 3 randomized clinical trial. JAMA oncology, 6(7), . https://doi.org/10.1001/jamaoncol.2020.1024
Chicago-Zitierstil (17. Ausg.)Reardon, David A., et al. "Effect of Nivolumab Vs Bevacizumab in Patients with Recurrent Glioblastoma: The Checkmate 143 Phase 3 Randomized Clinical Trial." JAMA Oncology 6, no. 7 (2020). https://doi.org/10.1001/jamaoncol.2020.1024.
MLA-Zitierstil (9. Ausg.)Reardon, David A., et al. "Effect of Nivolumab Vs Bevacizumab in Patients with Recurrent Glioblastoma: The Checkmate 143 Phase 3 Randomized Clinical Trial." JAMA Oncology, vol. 6, no. 7, 2020, https://doi.org/10.1001/jamaoncol.2020.1024.